chartexchange

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

GlobeNewswire Inc. | Nov 5, 2026 8:00 AM EST

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.

Read original article